SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.

Peters S, Hochmair M, Arbour KC, Rodriguez LP, Reck M, Leal T, R Lindsay C, Shun L, William WN, Spira AI, Sabari JK, Henning Grønberg B, Nishio M, Burns TF, Girard N, Capuzzo F, Merced A, Fasnacht N, Visseren-Grul C, Negrao MV

Open source

DOI: 10.1080/14796694.2026.2651961
Published: 2026 Apr
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2651961,
  title = {SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.},
  author = {Peters S and Hochmair M and Arbour KC and Rodriguez LP and Reck M and Leal T and R Lindsay C and Shun L and William WN and Spira AI and Sabari JK and Henning Grønberg B and Nishio M and Burns TF and Girard N and Capuzzo F and Merced A and Fasnacht N and Visseren-Grul C and Negrao MV},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2651961},
  url = {https://doi.org/10.1080/14796694.2026.2651961}
}

RIS

TY  - JOUR
TI  - SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.
AU  - Peters S
AU  - Hochmair M
AU  - Arbour KC
AU  - Rodriguez LP
AU  - Reck M
AU  - Leal T
AU  - R Lindsay C
AU  - Shun L
AU  - William WN
AU  - Spira AI
AU  - Sabari JK
AU  - Henning Grønberg B
AU  - Nishio M
AU  - Burns TF
AU  - Girard N
AU  - Capuzzo F
AU  - Merced A
AU  - Fasnacht N
AU  - Visseren-Grul C
AU  - Negrao MV
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2651961
UR  - https://doi.org/10.1080/14796694.2026.2651961
ER  -

APA

S, P., M, H., KC, A., LP, R., M, R., T, L., C, R. L., L, S., WN, W., AI, S., JK, S., B, H. G., M, N., TF, B., N, G., F, C., A, M., N, F., C, V., & MV, N. (2026). SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2651961

Source records

pubmed · retrieved 2026-09-26T14:37:38.469Z
europe-pmc · retrieved 2026-09-26T14:37:38.468Z